Verrica Pharmaceuticals (VRCA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.60, -4.89% vs the prior close of $3.78.
- Volume 116.47K shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VRCA slides 4.9% to $3.60. Closed at $3.60, -4.89% vs the prior close of $3.78. Day range $3.48–$3.95, opened at $3.85.
VRCA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VRCA slides 4.9% to $3.60
- Closed at $3.60, -4.89% vs the prior close of $3.78. Day range $3.48–$3.95, opened at $3.85.
- Volume was 116.47K shares, 1.5x its 50-day average of 76.04K.
- Price is -23.5% vs its 50-day average ($4.70) and -38.4% vs its 200-day average ($5.84).
- 52-week range $3.28–$9.82; today's close sits at 5% of that range, 63.4% below the 52-week high.
Oct 15, 2026 — VRCA dips 1.3% to $3.78
- Closed at $3.78, -1.31% vs the prior close of $3.83. Day range $3.75–$3.95, opened at $3.92.
- Volume was 64.30K shares, 0.9x its 50-day average of 74.99K.
- Price is -20.2% vs its 50-day average ($4.74) and -35.5% vs its 200-day average ($5.86).
- 52-week range $3.28–$9.82; today's close sits at 8% of that range, 61.5% below the 52-week high.
Oct 14, 2026 — VRCA jumps 7.0% to $3.83
- Closed at $3.83, +6.98% vs the prior close of $3.58. Day range $3.50–$3.92, opened at $3.54.
- Volume was 54.00K shares, 0.7x its 50-day average of 74.48K.
- Price is -19.7% vs its 50-day average ($4.77) and -34.9% vs its 200-day average ($5.89).
- 52-week range $3.28–$9.82; today's close sits at 8% of that range, 61.0% below the 52-week high.
Oct 13, 2026 — VRCA slides 10.7% to $3.58, a 6-month low, 3 down days in a row
- Closed at $3.58, -10.72% vs the prior close of $4.01. Day range $3.51–$4.38, opened at $3.99.
- Volume was 82.80K shares, 1.1x its 50-day average of 73.47K.
- Price is -25.5% vs its 50-day average ($4.80) and -39.4% vs its 200-day average ($5.91).
- 52-week range $3.28–$9.82; today's close sits at 5% of that range, 63.5% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — VRCA dips 2.4% to $4.01, a 6-month low
- Closed at $4.01, -2.43% vs the prior close of $4.11. Day range $4.00–$4.20, opened at $4.20.
- Volume was 48.10K shares, 0.7x its 50-day average of 72.61K.
- Price is -17.1% vs its 50-day average ($4.84) and -32.4% vs its 200-day average ($5.93).
- 52-week range $3.28–$9.82; today's close sits at 11% of that range, 59.2% below the 52-week high.
Oct 9, 2026 — VRCA dips 1.7% to $4.11, a 6-month low
- Closed at $4.11, -1.67% vs the prior close of $4.18. Day range $4.06–$4.37, opened at $4.37.
- Volume was 46.60K shares, 0.6x its 50-day average of 71.81K.
- Price is -15.4% vs its 50-day average ($4.86) and -30.9% vs its 200-day average ($5.95).
- 52-week range $3.28–$9.82; today's close sits at 13% of that range, 58.2% below the 52-week high.
Oct 8, 2026 — VRCA rises 1.0% to $4.18
- Closed at $4.18, +0.97% vs the prior close of $4.14. Day range $4.05–$4.29, opened at $4.14.
- Volume was 37.20K shares, 0.5x its 50-day average of 71.69K — lighter than usual.
- Price is -14.4% vs its 50-day average ($4.88) and -30.0% vs its 200-day average ($5.97).
- 52-week range $3.28–$9.82; today's close sits at 14% of that range, 57.4% below the 52-week high.
Oct 7, 2026 — VRCA dips 1.7% to $4.14, a 6-month low, 5 down days in a row
- Closed at $4.14, -1.66% vs the prior close of $4.21. Day range $4.06–$4.33, opened at $4.15.
- Volume was 47.60K shares, 0.7x its 50-day average of 71.71K.
- Price is -15.6% vs its 50-day average ($4.90) and -30.9% vs its 200-day average ($5.99).
- 52-week range $3.28–$9.82; today's close sits at 13% of that range, 57.8% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — VRCA dips 2.3% to $4.21, a 6-month low, 4 down days in a row
- Closed at $4.21, -2.32% vs the prior close of $4.31. Day range $4.17–$4.41, opened at $4.36.
- Volume was 40.60K shares, 0.6x its 50-day average of 72.94K — lighter than usual.
- Price is -14.6% vs its 50-day average ($4.93) and -29.9% vs its 200-day average ($6.01).
- 52-week range $3.28–$9.82; today's close sits at 14% of that range, 57.1% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — VRCA dips 1.6% to $4.31, a 6-month low, 3 down days in a row
- Closed at $4.31, -1.60% vs the prior close of $4.38. Day range $4.25–$4.54, opened at $4.34.
- Volume was 34.30K shares, 0.5x its 50-day average of 72.59K — lighter than usual.
- Price is -12.9% vs its 50-day average ($4.95) and -28.5% vs its 200-day average ($6.03).
- 52-week range $3.28–$9.82; today's close sits at 16% of that range, 56.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — VRCA dips 3.0% to $4.38
- Closed at $4.38, -2.99% vs the prior close of $4.51. Day range $4.37–$4.84, opened at $4.56.
- Volume was 44.10K shares, 0.6x its 50-day average of 72.05K.
- Price is -11.8% vs its 50-day average ($4.96) and -27.6% vs its 200-day average ($6.05).
- 52-week range $3.28–$9.82; today's close sits at 17% of that range, 55.4% below the 52-week high.
VRCA latest news & SEC filings
Every SEC filing by or about VRCA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zawitz David bought 6,000 shares at $4.98 (≈$29.88K) on Aug 17, 2026
- Zawitz David bought 6,000 shares at $4.98 (≈$29.88K) on Aug 17, 2026
- Zawitz David bought 6,000 shares at $4.98 (≈$29.88K) on Aug 17, 2026
- Zawitz David bought 6,000 shares at $4.98 (≈$29.88K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Rieger Jayson bought 5,000 shares at $4.91 (≈$24.55K) on Aug 17, 2026
- Rieger Jayson bought 5,000 shares at $4.91 (≈$24.55K) on Aug 17, 2026
- Rieger Jayson bought 5,000 shares at $4.91 (≈$24.55K) on Aug 17, 2026
- Rieger Jayson bought 5,000 shares at $4.91 (≈$24.55K) on Aug 17, 2026
- Rieger Jayson bought 20,000 shares at $5.06 (≈$101.20K) on Aug 14, 2026
- Rieger Jayson bought 20,000 shares at $5.06 (≈$101.20K) on Aug 14, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Rosenberg Noah L. bought 2,030 shares at $4.92 (≈$9.99K) on Aug 18, 2026
- Rosenberg Noah L. bought 2,030 shares at $4.92 (≈$9.99K) on Aug 18, 2026
- Rosenberg Noah L. bought 2,030 shares at $4.92 (≈$9.99K) on Aug 18, 2026
- Rosenberg Noah L. bought 2,030 shares at $4.92 (≈$9.99K) on Aug 18, 2026
- Rosenberg Noah L. bought 4,200 shares at $4.91 (≈$20.62K) on Aug 17, 2026
- Rosenberg Noah L. bought 4,200 shares at $4.91 (≈$20.62K) on Aug 17, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kirby John J. bought 5,000 shares at $4.93 (≈$24.65K) on Aug 18, 2026
- Kirby John J. bought 5,000 shares at $4.93 (≈$24.65K) on Aug 18, 2026
- Kirby John J. bought 5,000 shares at $4.93 (≈$24.65K) on Aug 18, 2026
- Kirby John J. bought 5,000 shares at $4.93 (≈$24.65K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $5.86M (prior year $12.70M) (-53.8% vs Jun 30, 2025)
- Net income: -$13.15M (prior year $204.00K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.62 (prior year $0.02) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade VRCA
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 11, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.66% (largest 10.7%). That is a volatile stock.
- Liquidity: about 50.40K shares (≈$181.18K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.60 vs a range of $3.28–$9.82 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Jul 25, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Noah L. Rosenberg bought 2,030 shares on Aug 18, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 9, 2026.
- Share count: 17.18M shares outstanding (Jul 31, 2026), +81.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VRCA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.85 | 3.95 | 3.48 | 3.60 | 116.47K |
| Oct 15, 2026 | 3.92 | 3.95 | 3.75 | 3.78 | 64.30K |
| Oct 14, 2026 | 3.54 | 3.92 | 3.50 | 3.83 | 54.00K |
| Oct 13, 2026 | 3.99 | 4.38 | 3.51 | 3.58 | 82.80K |
| Oct 12, 2026 | 4.20 | 4.20 | 4.00 | 4.01 | 48.10K |
| Oct 9, 2026 | 4.37 | 4.37 | 4.06 | 4.11 | 46.60K |
| Oct 8, 2026 | 4.14 | 4.29 | 4.05 | 4.18 | 37.20K |
| Oct 7, 2026 | 4.15 | 4.33 | 4.06 | 4.14 | 47.60K |
| Oct 6, 2026 | 4.36 | 4.41 | 4.17 | 4.21 | 40.60K |
| Oct 5, 2026 | 4.34 | 4.54 | 4.25 | 4.31 | 34.30K |
| Oct 2, 2026 | 4.56 | 4.84 | 4.37 | 4.38 | 44.10K |
| Oct 1, 2026 | 4.85 | 4.85 | 4.51 | 4.51 | 54.50K |
| Sep 30, 2026 | 4.51 | 5.04 | 4.51 | 4.80 | 51.00K |
| Sep 29, 2026 | 4.67 | 4.67 | 4.45 | 4.46 | 3.70K |
| Sep 28, 2026 | 4.33 | 4.63 | 4.32 | 4.60 | 33.00K |
| Sep 25, 2026 | 4.39 | 4.50 | 4.36 | 4.37 | 72.80K |
| Sep 24, 2026 | 4.62 | 4.64 | 4.36 | 4.36 | 40.90K |
| Sep 23, 2026 | 4.67 | 4.78 | 4.55 | 4.62 | 41.30K |
| Sep 22, 2026 | 4.50 | 4.90 | 4.50 | 4.72 | 65.10K |
| Sep 21, 2026 | 4.55 | 4.64 | 4.40 | 4.49 | 29.60K |
About Verrica Pharmaceuticals
Verrica Pharmaceuticals (VRCA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WEST CHESTER, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1660334.
VRCA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gavin Corcoran | Director | Jun 9, 2026 |
| Lawrence Eichenfield | Director | Jun 9, 2026 |
| Charles Frantzreb | Director | Dec 30, 2025 |
| Paul B Manning | Director | Nov 25, 2025 |
| Diem Nguyen | Director | Jun 9, 2026 |
| Mark A Sr Prygocki | Director | Jun 9, 2026 |
| Jayson Rieger | CEO and President | Aug 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John J. Kirby | Interim CFO | Aug 18, 2026 |
| Jayson Rieger | CEO and President | Aug 18, 2026 |
| Noah L. Rosenberg | CMO | Aug 18, 2026 |
| David Zawitz | Chief Operating Officer | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Noah L. Rosenberg | Buy | 2,030 | $4.92 |
| Aug 18, 2026 | Noah L. Rosenberg | Buy | 2,030 | $4.92 |
| Aug 18, 2026 | Noah L. Rosenberg | Buy | 2,030 | $4.92 |
| Aug 18, 2026 | Noah L. Rosenberg | Buy | 2,030 | $4.92 |
| Aug 18, 2026 | John J. Kirby | Buy | 5,000 | $4.93 |
| Aug 18, 2026 | John J. Kirby | Buy | 5,000 | $4.93 |
| Aug 18, 2026 | John J. Kirby | Buy | 5,000 | $4.93 |
| Aug 18, 2026 | John J. Kirby | Buy | 5,000 | $4.93 |
| Aug 17, 2026 | Jayson Rieger | Buy | 5,000 | $4.91 |
| Aug 17, 2026 | Jayson Rieger | Buy | 5,000 | $4.91 |
| Aug 17, 2026 | Jayson Rieger | Buy | 5,000 | $4.91 |
| Aug 17, 2026 | Jayson Rieger | Buy | 5,000 | $4.91 |
| Aug 17, 2026 | Noah L. Rosenberg | Buy | 4,200 | $4.91 |
| Aug 17, 2026 | Noah L. Rosenberg | Buy | 4,200 | $4.91 |
| Aug 17, 2026 | Noah L. Rosenberg | Buy | 4,200 | $4.91 |
VRCA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-17.89M | -1.68 | $-17.63M |
| Dec 31, 2024 | $7.57M | $-76.58M | -14.78 | $-60.93M |
| Dec 31, 2023 | $5.12M | $-67.00M | -1.48 | $-38.58M |
| Dec 31, 2022 | $9.03M | $-24.49M | -0.72 | $-18.65M |
| Dec 31, 2021 | $12.00M | $-35.08M | -1.30 | $-27.58M |
Latest balance sheet: total assets $36.02M, total liabilities $31.71M, cash $11.20M (as of Jun 30, 2026).
VRCA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.36 |
| May 12, 2026 | 8-K Item 2.02 (results) | $7.15 |
| Mar 11, 2026 | 8-K Item 2.02 (results) | $6.26 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $3.93 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $6.82 |
| May 13, 2025 | 8-K Item 2.02 (results) | $5.50 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $6.48 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $14.30 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VRCA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.